Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell has disclosed a change in the interests of managing director Paul Anderson, who holds securities both directly and indirectly through family-related entities including the Elwing Superannuation Fund and the Elwing Family Trust. The filing shows that 126,580 short-term performance rights expiring in November 2027 have vested and been exercised into an equivalent number of ordinary shares at no cash consideration, reflecting the satisfaction of preset performance conditions and increasing Anderson’s direct equity exposure while reducing his performance rights balance; the move underscores ongoing alignment between executive remuneration and shareholder outcomes but does not involve any on-market trading or changes to contractual interests.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is an Australian biotechnology company focused on regenerative medicine, developing and commercialising products that repair and regenerate soft tissues, such as tendons, nerves and cartilage, for orthopaedic and musculoskeletal conditions. The company targets specialist medical markets, working with surgeons and healthcare providers to bring cell-based therapies and related technologies to domestic and international patients.
Average Trading Volume: 812,156
Technical Sentiment Signal: Buy
Current Market Cap: A$290.1M
See more insights into OCC stock on TipRanks’ Stock Analysis page.